Magenta Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Magenta Therapeutics, Inc.

Magenta Therapeutics, Inc. (ticker: MGTA) is a U.S.-listed biotechnology issuer associated with the NASDAQ market in the United States. For investors, the key point is that the listed shell formerly known as Magenta underwent a major strategic reset after a 2023 reverse merger, and the operating business of the combined company became primarily the business of Dianthus Therapeutics. As a result, MGTA should be viewed through the lens of a transformed public vehicle with a corporate history rooted in the Cambridge, Massachusetts biotech ecosystem, rather than as a plain-vanilla single-product biotech story. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1690585/000095017024034681/dnth-20231231.htm?utm_source=openai)) From a sector perspective, MGTA belongs in Health & Pharma. The company’s legacy identity was formed around developing advanced cell- and immune-related therapies, and its historical base was in Cambridge, Massachusetts, a core U.S. life-sciences hub. That location matters: it provides access to talent, academic collaborators, clinical expertise, and specialist capital. Magenta was incorporated in 2015, and that early-stage biotech origin still frames how investors should think about the company’s risk profile and value creation path. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1690585/000095017024034681/dnth-20231231.htm?utm_source=openai)) Operationally, the post-restructuring company is focused on next-generation complement therapeutics for severe autoimmune and inflammatory diseases. SEC filings describe the lead proprietary monoclonal antibody candidate as DNTH103, designed to selectively target the active form of C1s in the complement pathway and, in principle, improve efficacy, safety, and dosing convenience versus current or emerging therapies. That places the business in a highly competitive specialty-immunology niche where clinical differentiation, trial execution, and regulatory progress are more important than near-term revenue generation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1690585/000095017024034681/dnth-20231231.htm?utm_source=openai)) In competitive terms, the company operates in a field dominated by larger and better-funded biotech and pharmaceutical peers, but its niche focus can be attractive if the clinical profile is strong. The market opportunity is tied to complement-mediated diseases, where investors typically look for clear biomarker-driven differentiation, durable efficacy, and convenient dosing. MGTA’s strategy therefore appears centered on a focused pipeline rather than broad diversification, which increases both upside potential and binary development risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1690585/000095017024034681/dnth-20231231.htm?utm_source=openai)) Recent milestones are material. In September 2023, the reverse merger changed the company’s name from Magenta Therapeutics, Inc. to Dianthus Therapeutics, Inc., and the business became primarily that of the former Dianthus operating company. In January 2024, the company completed a private placement that brought in roughly $230 million through common shares and pre-funded warrants, strengthening the balance sheet to fund development programs. For investors tracking SEC Form 4 insider activity, these events are important context because they reflect a company in transition, with capital formation and clinical development now central to the equity story. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1690585/000095017024034681/dnth-20231231.htm?utm_source=openai))